share_log

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm周六在ASCO 2024上介绍了SIENDO关于晚期或复发性TP53野生型子宫内膜癌研究的最新探索性亚组分析
Benzinga ·  06/02 14:37

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm周六在ASCO 2024上介绍了SIENDO关于晚期或复发性TP53野生型子宫内膜癌研究的最新探索性亚组分析

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发